Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model

[21] Wang Y(2011)Association of genetic variants in six candidate genes with valproic acid therapy optimization Pharmacogenomics 12 1107-743

[22] Lin W(2017)Population pharmacokinetic modelling of valproic acid and its selected metabolites in acute VPA poisoning Pharmacol Rep 69 340-182

[23] Wang C(2017)Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy Seizure 51 22-584

[24] Zhao L(2016)Effects of UGT1A6 and GABRA1 on standardized valproic acid plasma concentrations and treatment effect in children with epilepsy in China Ther Drug Monit 38 738-569

[25] Li X(2001)Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies Clin Pharmacol Ther 70 175-192

[26] Zhao Z(2001)High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry Proc Natl Acad Sci U S A 98 581-623

[27] Miao L(2009)Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions AAPS J 11 558-330

[28] Jiao Z(2001)Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check J Pharmacokinet Pharmacodyn 28 171-241

[29] Williams JH(2003)Model appropriateness and population pharmacokinetic modeling J Clin Pharmacol 43 610-15422

[30] Jayaraman B(2012)The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007 Clin Pharmacokinet 51 319-598

[21] Wang Y(2011)Association of genetic variants in six candidate genes with valproic acid therapy optimization Pharmacogenomics 12 1107-743

[22] Lin W(2017)Population pharmacokinetic modelling of valproic acid and its selected metabolites in acute VPA poisoning Pharmacol Rep 69 340-182

[23] Wang C(2017)Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy Seizure 51 22-584

[24] Zhao L(2016)Effects of UGT1A6 and GABRA1 on standardized valproic acid plasma concentrations and treatment effect in children with epilepsy in China Ther Drug Monit 38 738-569

[25] Li X(2001)Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies Clin Pharmacol Ther 70 175-192

[26] Zhao Z(2001)High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry Proc Natl Acad Sci U S A 98 581-623

[27] Miao L(2009)Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions AAPS J 11 558-330

[28] Jiao Z(2001)Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check J Pharmacokinet Pharmacodyn 28 171-241

[29] Williams JH(2003)Model appropriateness and population pharmacokinetic modeling J Clin Pharmacol 43 610-15422

[30] Jayaraman B(2012)The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007 Clin Pharmacokinet 51 319-598